Skip to content

Ishara Investments LP

Follow

13F filer, CIK 2111609, LOS ANGELES, CA

Ishara Investments LP reported $121,006,810 across 41 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 50.19% of the portfolio.

Accepted , ingested 13F-HR 0002111609-26-000005

Period
2026-09-30
Reported value
$121M
Holdings
41
Top 10 weight
50.19%
New
17
Sold out
17

Largest buys vs the previous quarter

SecurityShares changeApprox. value
CYTKadded+95,200$6.27M
TARSnew+70,000$5.5M
PTCTnew+80,000$5.18M
ARQTnew+180,000$4.76M
VERAadded+139,750$4.51M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
XERSreduced-830,000-$7.93M
AGIOexited-164,000-$6.09M
BMRNreduced-95,500-$5.73M
INSMexited-51,250-$5.46M
CRNXexited-143,500-$5.37M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0002111609-26-000005, largest first. % of portfolio is the value over $119,503,810, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
TVTXTRAVERE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: 110,700 shares; 2026Q2: 82,000 shares; 2026Q3: 145,000 shares 145,000$8.54M7.14%+63,000Timeline
CYTKCYTOKINETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 32,800 shares; 2026Q3: 128,000 shares 128,000$8.44M7.06%+95,200Timeline
BBIOBRIDGEBIO PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 36,000 shares; 2026Q1: not reported; 2026Q2: 57,400 shares; 2026Q3: 100,000 shares 100,000$6.58M5.51%+42,600Timeline
ACADACADIA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 160,000 shares; 2026Q1: 123,000 shares; 2026Q2: 410,000 shares; 2026Q3: 320,000 shares 320,000$6.45M5.4%-90,000Timeline
TARSTARSUS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 24,000 shares; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 70,000 shares 70,000$5.5M4.6%newTimeline
PTCTPTC THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 36,000 shares; 2026Q1: 10,250 shares; 2026Q2: not reported; 2026Q3: 80,000 shares 80,000$5.18M4.34%newTimeline
PRAXPRAXIS PRECISION MEDICINES IQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 40,000 shares; 2026Q1: 22,550 shares; 2026Q2: 22,550 shares; 2026Q3: 17,000 shares 17,000$4.95M4.14%-5,550Timeline
VERAVERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: 82,000 shares; 2026Q2: 10,250 shares; 2026Q3: 150,000 shares 150,000$4.84M4.05%+139,750Timeline
ARQTARCUTIS BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 12,000 shares; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 180,000 shares 180,000$4.76M3.98%newTimeline
ANNXANNEXON INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 750,000 shares; 2026Q1: 174,250 shares; 2026Q2: 820,000 shares; 2026Q3: 1,120,000 shares 1,120,000$4.74M3.96%+300,000Timeline
UTHRUNITED THERAPEUTICS CORP DELQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 5,500 shares; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 8,000 shares 8,000$4.34M3.63%newTimeline
NAMSNEWAMSTERDAM PHARMA COMPANYQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 30,000 shares; 2026Q1: 36,900 shares; 2026Q2: 36,900 shares; 2026Q3: 160,000 shares 160,000$3.89M3.26%+123,100Timeline
XERSXERIS BIOPHARMA HOLDINGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 800,000 shares; 2026Q1: 1,025,000 shares; 2026Q2: 1,230,000 shares; 2026Q3: 400,000 shares 400,000$3.82M3.2%-830,000Timeline
CELCCELCUITY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 48,000 shares 48,000$3.82M3.19%newTimeline
DBVTDBV TECHNOLOGIES S AQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: 102,500 shares; 2026Q2: 184,500 shares; 2026Q3: 270,000 shares 270,000$3.18M2.66%+85,500Timeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 150,000 shares 150,000$3.09M2.58%newTimeline
ZNTLZENTALIS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 1,320,000 shares; 2026Q1: 1,230,000 shares; 2026Q2: 1,025,000 shares; 2026Q3: 1,080,000 shares 1,080,000$2.99M2.5%+55,000Timeline
BMRNBIOMARIN PHARMACEUTICAL INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 100,000 shares; 2026Q1: 82,000 shares; 2026Q2: 143,500 shares; 2026Q3: 48,000 shares 48,000$2.88M2.41%-95,500Timeline
BIIBBIOGEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 12,000 shares 12,000$2.71M2.27%newTimeline
MLYSMINERALYS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: 82,000 shares; 2026Q2: 102,500 shares; 2026Q3: 100,000 shares 100,000$2.51M2.1%-2,500Timeline
LGNDLIGAND PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: 8,200 shares; 2026Q2: not reported; 2026Q3: 8,000 shares 8,000$2.5M2.09%newTimeline
RAREULTRAGENYX PHARMACEUTICAL INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 50,000 shares; 2026Q1: 174,250 shares; 2026Q2: 205,000 shares; 2026Q3: 160,000 shares 160,000$2.4M2.01%-45,000Timeline
PCVXVAXCYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 50,000 shares; 2026Q1: 57,400 shares; 2026Q2: 82,000 shares; 2026Q3: 40,000 shares 40,000$2.28M1.9%-42,000Timeline
ORICORIC PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 160,000 shares; 2026Q1: 102,500 shares; 2026Q2: 123,000 shares; 2026Q3: 160,000 shares 160,000$2.16M1.8%+37,000Timeline
AXSMAXSOME THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: 41,000 shares; 2026Q2: 16,400 shares; 2026Q3: 10,000 shares 10,000$1.84M1.54%-6,400Timeline
SLNSILENCE THERAPEUTICS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 240,000 shares; 2026Q1: 140,500 shares; 2026Q2: 55,350 shares; 2026Q3: 160,000 shares 160,000$1.75M1.46%+104,650Timeline
BEAMBEAM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 50,000 shares; 2026Q1: 57,400 shares; 2026Q2: 41,000 shares; 2026Q3: 70,000 shares 70,000$1.71M1.43%+29,000Timeline
BHVNBIOHAVEN LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 88,000 shares; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 120,000 shares 120,000$1.6M1.34%newTimeline
CTNMCONTINEUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: 142,000 shares; 2026Q2: 205,000 shares; 2026Q3: 108,000 shares 108,000$1.45M1.21%-97,000Timeline
GMABGENMAB A/SQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 70,000 shares; 2026Q1: 82,000 shares; 2026Q2: 102,500 shares; 2026Q3: 40,000 shares 40,000$1.43M1.19%-62,500Timeline
NBIXNEUROCRINE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 8,000 shares 8,000$1.13M0.95%newTimeline
MNPRMONOPAR THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 12,300 shares; 2026Q3: 12,000 shares 12,000$956K0.8%-300Timeline
MLTXMOONLAKE IMMUNOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: 174,250 shares; 2026Q2: not reported; 2026Q3: 80,000 shares 80,000$936K0.78%newTimeline
SPRYARS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 143,490 shares; 2026Q3: 200,000 shares 200,000$862K0.72%+56,510Timeline
IONSIONIS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 16,000 shares 16,000$714K0.6%newTimeline
OLMAOLEMA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 30,000 shares; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 80,000 shares 80,000$691K0.58%newTimeline
LXRXLEXICON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 880,000 shares; 2026Q1: 902,000 shares; 2026Q2: 1,271,000 shares; 2026Q3: 320,000 shares 320,000$600K0.5%-951,000Timeline
WVEWAVE LIFE SCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 160,000 shares 160,000$592K0.5%newTimeline
SVRASAVARA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 80,000 shares 80,000$413K0.35%newTimeline
GOSSGOSSAMER BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 24,000 shares 24,000$284K0.24%newTimeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
RAREULTRAGENYX PHARMACEUTICAL IN COMput1,000$1.5Mnew

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
AGIOAGIOS PHARMACEUTICALS INC164,000$6.09Mshares
INSMINSMED INC51,250$5.46Mshares
CRNXCRINETICS PHARMACEUTICALS IN143,500$5.37Mshares
TNXPTONIX PHARMACEUTICALS HLDG C338,250$4.32Mshares
KURAKURA ONCOLOGY INC276,750$3.04Mshares
NUVBNUVATION BIO INC369,000$2.1Mshares
WVEWAVE LIFE SCIENCES LTD328,000$1.91Mshares
NKTRNEKTAR THERAPEUTICS26,650$1.86Mshares
SRRKSCHOLAR ROCK HLDG CORP30,750$1.69Mshares
ELVNENLIVEN THERAPEUTICS INC32,800$1.66Mshares
ALNYALNYLAM PHARMACEUTICALS INC5,125$1.54Mshares
SIONSIONNA THERAPEUTICS INC123,000$1.35Mshares
VRTXVERTEX PHARMACEUTICALS INC2,460$1.22Mshares
ERASERASCA INC41,000$751Kshares
IMTXIMMATICS N.V30,750$311Kshares
MREOMEREO BIOPHARMA GROUP PLC768,750$244Kshares
GOSSGOSSAMER BIO INC820,000$135Kshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0002111609-26-000005 base2026-11-16